Literature DB >> 24322554

Dyslipidaemia: 1-Year results from OSLER trial of anti-PCSK9 monoclonal antibody evolocumab.

Bryony M Mearns.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24322554     DOI： 10.1038/nrcardio.2013.201

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  1 in total

1.  Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.

Authors:  Michael J Koren; Robert P Giugliano; Frederick J Raal; David Sullivan; Michael Bolognese; Gisle Langslet; Fernando Civeira; Ransi Somaratne; Patric Nelson; Thomas Liu; Rob Scott; Scott M Wasserman; Marc S Sabatine
Journal:  Circulation       Date:  2013-11-19       Impact factor: 29.690
  1 in total
  4 in total

Review 1.  PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.

Authors:  Amand F Schmidt; Lucy S Pearce; John T Wilkins; John P Overington; Aroon D Hingorani; Juan P Casas
Journal:  Cochrane Database Syst Rev       Date:  2017-04-28

2.  PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.

Authors:  Amand F Schmidt; John-Paul L Carter; Lucy S Pearce; John T Wilkins; John P Overington; Aroon D Hingorani; J P Casas
Journal:  Cochrane Database Syst Rev       Date:  2020-10-20

Review 3.  Profile of evolocumab and its potential in the treatment of hyperlipidemia.

Authors:  Arrigo F G Cicero; Alessandro Colletti; Claudio Borghi
Journal:  Drug Des Devel Ther       Date:  2015-06-15       Impact factor: 4.162

Review 4.  Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.

Authors:  Marianne Abifadel; Sandy Elbitar; Petra El Khoury; Youmna Ghaleb; Mélody Chémaly; Marie-Line Moussalli; Jean-Pierre Rabès; Mathilde Varret; Catherine Boileau
Journal:  Curr Atheroscler Rep       Date:  2014-09       Impact factor: 5.967
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.